These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29336874)

  • 1. Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.
    Guibbal F; Bénard S; Patché J; Meneyrol V; Couprie J; Yong-Sang J; Meilhac O; Jestin E
    Bioorg Med Chem Lett; 2018 Feb; 28(4):787-792. PubMed ID: 29336874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
    Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
    Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active site competition is the mechanism for the inhibition of lipoprotein-associated phospholipase A
    Zhuo S; Yuan C
    Sci Rep; 2020 Oct; 10(1):17232. PubMed ID: 33057060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of imidazole and triazole derivatives as Lp-PLA₂ inhibitors and the unexpected discovery of highly potent quaternary ammonium salts.
    Wang K; Xu W; Liu Y; Zhang W; Wang W; Shen J; Wang Y
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1187-92. PubMed ID: 23385210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
    Lv SL; Zeng ZF; Gan WQ; Wang WQ; Li TG; Hou YF; Yan Z; Zhang RX; Yang M
    Acta Pharmacol Sin; 2021 Dec; 42(12):2016-2032. PubMed ID: 34226664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
    Liu Q; Chen X; Chen W; Yuan X; Su H; Shen J; Xu Y
    J Med Chem; 2016 May; 59(10):5115-20. PubMed ID: 27078579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic inhibition of lipoprotein-associated phospholipase A
    Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
    Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.
    Fenning RS; Burgert ME; Hamamdzic D; Peyster EG; Mohler ER; Kangovi S; Jucker BM; Lenhard SC; Macphee CH; Wilensky RL
    J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25672369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.
    Wang K; Xu W; Zhang W; Mo M; Wang Y; Shen J
    Bioorg Med Chem Lett; 2013 May; 23(10):2897-901. PubMed ID: 23575276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
    Daida H; Iwase T; Yagi S; Ando H; Nakajima H
    Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darapladib.
    Bui QT; Wilensky RL
    Expert Opin Investig Drugs; 2010 Jan; 19(1):161-8. PubMed ID: 20001561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
    Wang GH; Jin J; Sun LZ
    Endocr J; 2018 Sep; 65(9):903-913. PubMed ID: 29925744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
    Ferri N; Corsini A
    G Ital Cardiol (Rome); 2014 Dec; 15(12):664-9. PubMed ID: 25533115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of Lp-PLA2 in lipid-lowering therapy.
    Racherla S; Arora R
    Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
    Riley RF; Corson MA
    IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal pathology is associated with increased blood-retina barrier permeability in a diabetic and hypercholesterolaemic pig model: Beneficial effects of the LpPLA
    Acharya NK; Qi X; Goldwaser EL; Godsey GA; Wu H; Kosciuk MC; Freeman TA; Macphee CH; Wilensky RL; Venkataraman V; Nagele RG
    Diab Vasc Dis Res; 2017 May; 14(3):200-213. PubMed ID: 28301218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
    Yeo A; Li L; Warren L; Aponte J; Fraser D; King K; Johansson K; Barnes A; MacPhee C; Davies R; Chissoe S; Tarka E; O'Donoghue ML; White HD; Wallentin L; Waterworth D
    PLoS One; 2017; 12(7):e0182115. PubMed ID: 28753643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model.
    Wihastuti TA; Heriansyah T; Hanifa H; Andarini S; Sholichah Z; Sulfia YH; Adam AA; Refialdinata J; Lutfiana NC
    Endocr Regul; 2018 Apr; 52(2):69-75. PubMed ID: 29715185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.
    Hu MM; Zhang J; Wang WY; Wu WY; Ma YL; Chen WH; Wang YP
    Acta Pharmacol Sin; 2011 Oct; 32(10):1253-8. PubMed ID: 21970837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.